We had a fantastic time at EUROTOX 2024, held from 8 – 11th September in the picturesque city of Copenhagen, Denmark. This year’s theme, “Toxicology – A Quest for Safe Chemicals and Medicines”, was reflected in the diverse sessions, posters and presentations throughout the event. Key topics ranged from the safety of drugs and environmental […]
EUROTOX 2024: Advancing toxicology in Copenhagen Read More »
Developmental and reproductive toxicity (DART) is a critical area of toxicology that is required to assess the impact of new chemicals on adult fertility and embryo development. Industries across the globe rely on DART assessments to safeguard human health, adhering to regulatory standards like those outlined in the ICH S5 (R3) guideline. However, the current
A step towards animal-free developmental and reproductive toxicity safety assessments Read More »
For over four decades, at Lhasa Limited we have been developing scientific software solutions that enable scientists to make informed decisions on the safety of drugs, chemicals and cosmetics. Our journey advanced significantly with the creation of Derek Nexus, an in silico expert knowledge-based toxicity prediction tool. As regulatory landscapes evolved and the push for
10 frequently asked questions about Derek Nexus, answered Read More »
Cannabidiol (CBD) is gaining prominence as a sought-after ingredient in skincare and beauty formulations, thanks to its notable anti-inflammatory, antioxidant and anti-bacterial properties. Derived directly from the hemp plant, this compound is increasingly being used as an ingredient in skincare products, particularly for the management of various skin conditions like eczema, dermatitis and psoriasis. Despite
Supporting the safe use of CBD in skincare products using Derek Nexus Read More »
One of our three Lhasa Limited posters during the recent Society of Toxicology 63rd annual meeting was selected for the top 10 best risk assessment abstract award by the Risk Assessment Speciality Section! Authored by Lhasa scientist, Pooja Tomar, the poster titled “Best practice for conducting expert review of sensitisation data and predictions” highlights the critical
Throughout 2023, our dedicated team contributed significantly to various journals through authoring and co-authoring a plethora of publications. Here are the articles, as voted by our members, which stood out above the rest. Organised into 5 compelling categories; Extractables and Leachables, Nitrosamines, Potentially Mutagenic Impurities (PMIs), Data Sharing and Safety Profiling in Drug Discovery, we
The ultimate 2024 reading list, as chosen by our members! Read More »
Building on the success of our recent webinar, How to establish acceptable intake (AI) limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs), we’re thrilled to present a follow-up that brings you closer to the insightful discussions that unfolded during the interactive Q&A session. In this blog, we’ve gathered questions posed during the webinar and curated written
Q&A deep dive with Martin Walter: How to establish AI limits for NDSRIs Read More »
Did you know that organosilicon compounds have a multitude of benefits within the health care industry? They are often used in prosthetics and artificial joints, as coatings on syringes and hypodermic needles, and as materials for implantable medical devices such as pacemakers and insulin pumps. With a unique set of performance properties, such as being
Silicone science meets in silico tools Read More »
In our ongoing commitment to serving our members and delivering public value, Lhasa Application Scientists, Fernanda Waechter, Manya Arora and Rushali Shinde embarked on an exciting trip to connect with our valued members in India! Travelling to two of India’s most vibrant and influential cities, Mumbai and Hyderabad, the trio met with 8 of Lhasa’s
Connecting with our members in India Read More »
In our earlier instalments of the Lhasa blog, we have discussed the latest regulatory insights presented by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada regarding acceptable intake limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs). Now, our focus zeroes in on the Enhanced Ames Test (EAT) and its
Current status of the Ames test for N-nitrosamines Read More »
Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK
Tel: +44 (0)113 394 6020
© 2024 Lhasa Limited, All rights reserved | Company registration number: 01765239 |
VAT number: 396 8737 77 | Registered charity number: 290866 | Governing documents